INTRODUCTION

Impact of Biomarkers, Proteomics, and Genomics in Cardiovascular Disease  F.S. Apple, S. Blankenberg, and D.A. Morrow  1

EDITORIALS

Growth Differentiation Factor 15: A Canary in a Coal Mine?  J.E. Ho and T.J. Wang (see article on page 172)  3

Statins, Plasma Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Lowering A. Khera (see article on page 183)  6

Delta Cardiac Troponin Values in Practice: Are We Ready to Move Absolutely Forward to Clinical Routine?  F.S. Apple and D.A. Morrow (see article on page 209)  8

INTERVIEW

An Interview with Dr. Eugene Braunwald  M. Landau  11

REFLECTION

Reflections on the Evolution of Cardiac Biomarkers  J.H. Ladenson  21

PERSPECTIVES

A Novel Technology for Measuring Cumulative Cardiac Biomarker Exposure over Time: What Happened When We Weren’t Looking?  C. deFilippi  25

Within Sight of a Rational Pipeline for Development of Protein Diagnostics  L. Anderson  28

Q&A


CLINICAL CASE STUDY


COMMENTARIES

S.W. Sharkey  43

J. Ordonez-Llanos  44

MINI-REVIEWS

Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future  S.A. Halim, L.K. Newby, and E.M. Ohman  45

Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays  F.S. Apple and P.O. Collinson, for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers  54

REVIEWS

Use of Natriuretic Peptides to Guide and Monitor Heart Failure Therapy  A.M. Richards and R.W. Troughton  62

Biomarkers and Cardiovascular Risk Assessment for Primary Prevention: An Update  L.G. Gilstrap and T.J. Wang  72

B-Type Natriuretic Peptide: From Posttranslational Processing to Clinical Measurement  J.P. Goetze  83


9p21 and the Genetic Revolution for Coronary Artery Disease  R. Roberts and A.F.R. Stewart  104

Next Steps in Cardiovascular Disease Genomic Research—Sequencing, Epigenetics, and Transcriptomics  R.B. Schnabel, A. Baccarelli, H. Lin, P.T. Ellinor, and E.J. Benjamin  113

Emerging Biomarkers in Heart Failure  R.R.J. van Kimmenade and J.L. Januzzi, Jr.  127

Metabolomics and Cardiovascular Biomarker Discovery  E.P. Rhee and R.E. Gerszten  139

OPINIONS

Troponin Release—Reversible or Irreversible Injury? Should We Care?  A.S. Jaffe and A.H.B. Wu  148

continued


PROTEOMICS AND PROTEIN MARKERS

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome  M. Mueller, M. Biener, M. Vafaie, S. Doerr, T. Keller, S. Blankenberg, H.A. Katus, and E. Giannitsis (see editorial on page 8)


ARTICLES, continued

Markers of Plaque Instability in the Early Diagnosis and Risk Stratification of Acute Myocardial Infarction

Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial
P. Kohli, M.P. Bonaca, R. Kakkar, A.Y. Kudinova, B.M. Scirica, M.S. Sabatine, S.A. Murphy, E. Braunwald, R.T. Lee, and D.A. Morrow

Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22
E.W. Grandin, P. Jarolim, S.A. Murphy, L. Ritterova, C.P. Cannon, E. Braunwald, and D.A. Morrow

Concordance, Variance, and Outliers in 4 Contemporary Cardiac Troponin Assays: Implications for Harmonization
J.P.J. Ungerer, L. Marquart, P.K. O’Rourke, U. Wilgen, and C.J. Pretorius

Troponin T Measurements by High-Sensitivity vs Conventional Assays for Risk Stratification in Acute Dyspnea

BRIEF COMMUNICATIONS

Comparison of Midregional Pro–A-Type Natriuretic Peptide and the N-Terminal Pro–B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events

Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes
P.A. Kavsak, S.A. Hill, W.B. Supapol, P.J. Devereaux, and A. Worster

CITATION CLASSIC

Aspirin in the Primary Prevention of Myocardial Infarction
C.H. Hennekens

LETTERS TO THE EDITOR

Evidence-Based Laboratory Medicine: How Well Do Laboratories Follow Recommendations and Guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study

Copeptin Adds to High-Sensitivity Troponin T in Rapid Rule Out of Acute Myocardial Infarction
M. Möckel

Copeptin—A Novel Marker in Acute Myocardial Infarction
S. von Haehling, T. Stojakovic, and B. Bigalke

In Reply
M. Karakas, J.L. Januzzi, Jr., U. Hoffmann, and W. Koenig

High-Sensitivity Cardiac Troponin Assays—Change Is Important
P.A. Kavsak and A.S. Jaffe

In Reply
S.J. Aldous, A.M. Richards, L. Cullen, and M.P. Than

CLINICAL CHEMIST

UNVEILING THE RIGHT SIDE

A Heart-to-Heart Talk
U. Anand

SCIENCE IN THE ARTS

William Harvey and the Undercurrents of Science
M.H. Dominiczak
ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF CLINICAL CHEMISTRY

For more information go to http://www.aacc.org/applications/ccjacent

ON THE COVER Angiogram of a Healthy Heart. This special issue of Clinical Chemistry provides a comprehensive summation of the current and future impact of biomarkers, proteomics, and genomics in cardiovascular disease. In addition to reviews and original research reports, this special issue contains 3 opinion articles, a perspective, 2 point/counterpoint features, and 3 editorials. Additionally, the human side of the scientific study of cardiovascular disease is covered in a historical reflection on the evolution of cardiac biomarkers for the detection of acute myocardial infarction and an interview with Dr. Eugene Braunwald that captures the essence of this prominent cardiologist and scientist who has demonstrated a great zeal for life and provided an exceptionally strong role model for growing interdisciplinary partnerships between cardiology and laboratory medicine. In short, there is something for everyone in this issue. ©2011 Photo Researchers, Inc. Reproduced with permission.

Clinical Chemistry Journal Club
Selected articles made freely available, including helpful slides and key points for discussion in your Journal Club.


http://www.clinchem.org/cgi/content/article/57/12/1687

Access the article by using the link above and by selecting Supplemental Data and Journal Club in the right-hand column.

Clinical Chemistry is now on Twitter, Facebook, and LinkedIn. Be a part of our community and receive updates on the latest issues, upcoming articles, podcasts, and more!

Technology Corner and color figures for Reviews sponsored by Department of Laboratory Medicine, Children’s Hospital Boston.

Clinical Chemistry podcast available at http://www.clinchem.org/